Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2003
03/13/2003US20030049302 Anticancer agent in intravagina device
03/13/2003US20030049301 Crosslinking collage
03/13/2003US20030049292 Hair treatments comprising zinc salts of piroctone olamine
03/13/2003US20030049287 Catechol oximes and their use in cosmetic and dermatological preparations
03/13/2003US20030049283 Scalp desensitizing formulation
03/13/2003US20030049281 Topical emulsion; quaternary ammonium salt emulsifier
03/13/2003US20030049272 Therapy for drug abruse; administering central nervous stimulant and mucous membrane irritation
03/13/2003US20030049266 Induce immunology response usin gpolynucleotide
03/13/2003US20030049261 Administering chitinase inhibitor
03/13/2003US20030049258 Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle
03/13/2003US20030049250 Anticholesterol agents, cardiovascular disorders; administering neuropeptide y
03/13/2003US20030049244 Method of utilizing neurotrophins to manipulate reproductive capacity
03/13/2003US20030049229 Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
03/13/2003US20030049227 Antitumor, anticarcinogenic agents; using fusion protein
03/13/2003US20030049226 Methods of treating syndrome x with aliphatic polyamines
03/13/2003US20030049205 That undergoes/interferes with cytochrome P450 metabolism, using d-threo-methylphenidate; side effect reduction of drug-drug interaction toxicity; tricyclic antidepressants or selective serotonin reuptake inhibitors
03/13/2003US20030049204 Individualization of therapy with gastroesophageal reflux disease agents
03/13/2003US20030049203 Targeted nucleic acid constructs and uses related thereto
03/13/2003US20030049158 Stablization and terminal sterilization of phospholipid formulations
03/13/2003CA2483959A1 Method for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo- and hydroxy-substituted hydrocarbons
03/13/2003CA2459822A1 Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents
03/13/2003CA2459728A1 Late gestation lung genes, fragments and uses thereof
03/13/2003CA2459584A1 Compositions and use thereof in the treatment of cancer
03/13/2003CA2459583A1 Compositions and methods of treatment of cancer
03/13/2003CA2459492A1 Anti-influenzal agent
03/13/2003CA2459406A1 Salvianolic acid b
03/13/2003CA2459346A1 Benzothiazepine derivatives
03/13/2003CA2459269A1 Stable episomal vectors
03/13/2003CA2459146A1 Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
03/13/2003CA2459136A1 A caspase-8 binding protein, its preparation and use
03/13/2003CA2459017A1 Medicinal compositions containing angiotensin ii receptor antagonist
03/13/2003CA2458995A1 Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
03/13/2003CA2458993A1 A method for the treatment or prevention of bone erosion
03/13/2003CA2458963A1 Increased solubility flavanolignan preparations
03/13/2003CA2458926A1 Methods of treating infection by drug resistant bacteria
03/13/2003CA2458915A1 Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer
03/13/2003CA2458808A1 Aminopyrrole compounds as antiinflammatory agents
03/13/2003CA2458807A1 Use of atazanavir in hiv therapy
03/13/2003CA2458805A1 Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer
03/13/2003CA2458798A1 Method for reducing hypertension and heart failure
03/13/2003CA2458780A1 Targeted nucleic acid constructs and uses related thereto
03/13/2003CA2458644A1 Crystaline clindamycin free base
03/13/2003CA2458555A1 Use of c2-substituted indane-1-one systems for producing medicaments for the prophylaxis or treatment of obesity
03/13/2003CA2458553A1 Use of polysubstituted indan-1-ol systems for producing drugs used in the prophylaxis or treatment of obesity
03/13/2003CA2458552A1 Use of derivatives of c2-substituted indan-1-ol systems for producing medicaments for the prophylaxis or the treatment of obesity
03/13/2003CA2458527A1 C2-substituted indane-1-ols and their derivatives, method for their production and their use as medicaments
03/13/2003CA2458526A1 Use of c2-substituted indane-1-ol systems for producing medicaments for the prophylaxis or treatment of obesity
03/13/2003CA2458523A1 C2-disubstituted indane-1-ol systems, method for their production and their use as medicaments
03/13/2003CA2458521A1 Derivatives of c2-substituted indan-1-ol systems, methods for the production thereof and their use as medicaments
03/13/2003CA2458459A1 Anti-cancer combinations
03/13/2003CA2458399A1 Cyclic indole and heteroindole derivatives, the production and use thereof as medicaments
03/13/2003CA2458348A1 Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain
03/13/2003CA2458213A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity
03/13/2003CA2458093A1 Urea and thiourea derivatives as non-nucleoside reverse transcriptase inhibitors
03/13/2003CA2457926A1 Pharmaceutical compositions for the treatment of asthma
03/13/2003CA2457922A1 Novel pyrazole analogs acting on cannabinoid receptors
03/13/2003CA2457861A1 Piperidine derivatives useful as ccr5 antagonists
03/13/2003CA2457540A1 Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degeneration
03/13/2003CA2457534A1 Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof
03/13/2003CA2457526A1 Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
03/13/2003CA2456904A1 Aerosolized decongestants for the treatment of sinusitis
03/13/2003CA2455896A1 Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma
03/13/2003CA2455126A1 Antineoplastic combinations
03/13/2003CA2454413A1 7-alkylidene-3-substituted-3-cephem-4-carboxylates as beta-lactamase inhibitors
03/13/2003CA2452438A1 4-thioxo-4,7-dihydro-thieno¬2,3-b|pyridine-5-carbothioamides as antiviral agents
03/13/2003CA2452431A1 4-thioxo-4,7-dihydro-thieno¬2,3-b|pyridine-5-carboxamides as antiviral agents
03/12/2003WO2002024654A1 Amino heterocyclic compounds (factor xa inhibitors 14)
03/12/2003WO2002022568A1 ss-THIO-AMINO ACIDS
03/12/2003EP1291430A1 Ceramide kinase and dna encoding the same
03/12/2003EP1291362A1 A complex between folic acid and polysaccharides, its preparation method and a pharmaceutical composition comprising said complex as active component
03/12/2003EP1291353A1 6-O-substituted ketolides having antibacterial activity
03/12/2003EP1291352A1 6-O-substituted ketolides having antibacterial activity
03/12/2003EP1291351A1 6-0 substituted ketolides having antibacterial activity
03/12/2003EP1291350A1 6-0 substituted ketolides having antibacterial activity
03/12/2003EP1291349A1 Malto-oligosaccharide derivatives and use thereof
03/12/2003EP1291346A1 Process for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties
03/12/2003EP1291345A1 Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
03/12/2003EP1291340A1 Phytosphingosine derivatives with antitumor activity
03/12/2003EP1291039A1 Use of a mixture of lidocaine and prilocaine and composition for tumescent local anesthesia
03/12/2003EP1291023A1 Sustained release compositions
03/12/2003EP1291018A1 Pharmaceutical composition
03/12/2003EP1291017A2 Use of statins to inhibit formation of osteoclasts
03/12/2003EP1291016A1 New use of modafinil and the d/l enantiomer
03/12/2003EP1291015A1 Dosage forms having prolonged active ingredient release
03/12/2003EP1291014A1 A process for producing a pharmaceutical solid preparation containing a poorly soluble drug
03/12/2003EP1291013A2 Storage-stable pharmaceutical compositions
03/12/2003EP1291008A2 Screening composition containing at least one dibenzoylmethane derivative and 1,1,1-tri-(2-methyl-4-hydroxy-5-tert-butylphenyl)-butane
03/12/2003EP1290952A1 Compositions for taking dietary fibers
03/12/2003EP1290204A1 Antisense modulation of c/ebp alpha expression
03/12/2003EP1290182A1 Sphingosine kinase and uses thereof
03/12/2003EP1290174A2 G-protein coupled receptor org3.
03/12/2003EP1290168A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
03/12/2003EP1290167A1 Human kcnq5 potassium channel, methods and compositions thereof
03/12/2003EP1290161A1 METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi
03/12/2003EP1290154A2 The identification and use of effectors and allosteric molecules for the alteration of gene expression
03/12/2003EP1290023A2 Nuclear factor kb inducing factor
03/12/2003EP1290021A2 Polynucleotide sequence encoding a putative cell adhesion molecule
03/12/2003EP1290017A2 Compositions and methods for delivery of a molecule into a cell
03/12/2003EP1290006A1 Combinatorial production of nucleotide and nucleoside (xitp)analogues
03/12/2003EP1289998A1 New process for the preparation of vinyl-pyrrolidinone cephalosporine derivatives
1 ... 5537 5538 5539 5540 5541 5542 5543 5544 5545 5546 5547 5548 5549 5550 5551 5552 5553 5554 5555 5556 5557 ... 7860